Sarc
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2003-01-01
- Employees
- -
- Market Cap
- -
SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes
- Conditions
- Interventions
- First Posted Date
- 2014-01-29
- Last Posted Date
- 2023-11-07
- Target Recruit Count
- 131
- Registration Number
- NCT02048371
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Sarcoma Oncology Research Center, Santa Monica, California, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide and/or Irinotecan Patients With Previously Treated, Incurable Ewing Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2014-01-23
- Last Posted Date
- 2021-01-12
- Target Recruit Count
- 34
- Registration Number
- NCT02044120
- Locations
- 🇺🇸
Children's Hospital of Los Angeles, Los Angeles, California, United States
🇺🇸Seattle's Children Cancer Center, Seattle, Washington, United States
🇬🇧University College London Hospital, London, United Kingdom
SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors)
- Conditions
- Interventions
- First Posted Date
- 2013-12-11
- Last Posted Date
- 2019-05-15
- Target Recruit Count
- 20
- Registration Number
- NCT02008877
- Locations
- 🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸University of Iowa, Iowa City, Iowa, United States
🇺🇸Huntsman Cancer Institute, Salt Lake City, Utah, United States
SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors
- Conditions
- Interventions
- First Posted Date
- 2012-08-09
- Last Posted Date
- 2019-03-06
- Target Recruit Count
- 25
- Registration Number
- NCT01661283
- Locations
- 🇺🇸
Ann and Robert Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
🇺🇸Pennsylvania Oncology Hematology Associates, Philadelphia, Pennsylvania, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) Patients
- First Posted Date
- 2009-12-14
- Last Posted Date
- 2013-09-09
- Target Recruit Count
- 5
- Registration Number
- NCT01031628
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸University of Iowa, Iowa City, Iowa, United States
🇺🇸Sarcoma Oncology Center, Santa Monica, California, United States
A Placebo-Controlled Study of Saracatinib (AZD0530) in Patients With Recurrent Osteosarcoma Localized to the Lung
- First Posted Date
- 2008-09-15
- Last Posted Date
- 2020-01-18
- Target Recruit Count
- 38
- Registration Number
- NCT00752206
- Locations
- 🇺🇸
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
🇺🇸UCLA/Mattel's Children's Hospital, Los Angeles, California, United States
Trial of Dasatinib in Advanced Sarcomas
- First Posted Date
- 2007-04-23
- Last Posted Date
- 2018-11-23
- Target Recruit Count
- 366
- Registration Number
- NCT00464620
- Locations
- 🇺🇸
Washington Cancer Institute, Washington, District of Columbia, United States
🇺🇸Arkansas Children's Hospital, Little Rock, Arkansas, United States
🇺🇸Kootenai Cancer Center, Coeur d'Alene, Idaho, United States
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors
- First Posted Date
- 2006-03-17
- Last Posted Date
- 2018-09-18
- Target Recruit Count
- 48
- Registration Number
- NCT00304083
- Locations
- 🇺🇸
UAB Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸Children's Memorial Hospital - Chicago, Chicago, Illinois, United States
🇺🇸Sarcoma Oncology Center, Santa Monica, California, United States
Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma
- Conditions
- Interventions
- First Posted Date
- 2006-01-25
- Last Posted Date
- 2014-12-01
- Target Recruit Count
- 47
- Registration Number
- NCT00282087
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Pennsylvania Oncology Hematology Associates, Philadelphia, Pennsylvania, United States
🇺🇸Massachusetts General, Boston, Massachusetts, United States
Neoadjuvant Imatinib in Dermatofibrosarcoma Protuberans
- First Posted Date
- 2005-10-21
- Last Posted Date
- 2012-03-29
- Target Recruit Count
- 18
- Registration Number
- NCT00243191
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Pennsylvania Onc/Hem Assoc., Philadelphia, Pennsylvania, United States
🇺🇸University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States